RecruitingNCT07457151

Danicopan PMS in Korea

Danicopan Regulatory Post-Marketing Study in Korea

Sponsor

AstraZeneca

Enrollment

8 participants

Start Date

Apr 10, 2026

Study Type

OBSERVATIONAL

Conditions

Paroxysmal nocturnal hemoglobinuria

Summary

As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with paroxysmal nocturnal hemoglobinuria. The study is currently recruiting participants at 5 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(4)

Research Site

Busan, South Korea

Research Site

Hwasun-gun, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07457151

Related Trials

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

NCT0574492145 locations

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

NCT0715474519 locations

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT0577647287 locations

A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

NCT074161623 locations

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT064124971 location